Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03413306|
Recruitment Status : Recruiting
First Posted : January 29, 2018
Last Update Posted : March 15, 2021
The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence.
The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy
|Condition or disease||Intervention/treatment||Phase|
|Acquired Aplastic Anemia||Drug: Eltrombopag Drug: IST (ATG + CsA)||Phase 3|
This trial will evaluate safety and efficacy of combination eltrombopag with standard hATG/CSA as first line therapy in patients with SAA. The primary endpoint is going to be estimating the rate of complete hematologic response at the point in four months after the end of the treatment. Secondary endpoints are probability of relapse, hematologic blood count recovery in 6 and 12 months after the treatment, survival, clonal evolution into myelodysplasia and leukemia
Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine (CsA), allowing to achieve a comparable long-term survival about 80%. However, one third of the patients treated with h-ATG/CsA, does not respond, and 25-30% of the responders relapse. The analysis of our clinical data suggests that majority of the hematologic responses observed following initial h-ATG/CsA are partial, with only a few patients achieving normal blood counts, and about 10% tend to have cyclosporine dependence. Although horse ATG/CsA provides represented a major advance in the treatment of SAA, such condition as refractory course of the disease, incomplete response, relapse, and clonal evolution limit the success of this treatment. Thus, new regimens are needed to overcome these limitations and provide a better alternative to stem cell transplantation.
One option of improving the quality of hematologic responses is influencing underlying stem cell function. Previous attempts to improve response by hematopoietic cytokines, including erythropoietin and G-CSF, have failed. Thrombopoietin is the principal endogenous regulator of platelet production. In addition, TPO also has stimulatory effects onto primitive multilineage progenitors and stem cells in vitro and animal models. Eltrombopag (Revolade), an oral 2nd generation small molecule TPO-agonist, is approved for treatment of chronic immune thrombocytopenic purpura and SAA who had insufficient response to immunosuppressive therapy. Eltrombopag increases platelets in healthy subjects and in thrombocytopenic patients, and recently has showed clinically significant hematologic responses in refractory SAA patients. The aim of this tudy to improve hematologic response rate and its quality, as well as to prevent late complications such as relapse and clonal progression, by adding eltrombopag into standard immunosuppressive therapy This trial evaluates safety and efficacy of combining eltrombopag with standard hATG/CSA as the first line of therapy in patients with SAA. The primary endpoint is going to be estimation of the rate of complete hematologic response in 4 months. Secondary endpoints are probability of relapse, robust hematologic blood count recovery in 6 and 12 months after the treatment, survival, clonal evolution to myelodysplasia and leukemia.
This is a trial aiming to increase 4 months overall response rate. The sample size is calculated on the hypothesis that the experimental treatment will increase the 4 months response rate in 20% in comparison with standard IST treatment arm. Under these assumptions, the sample size to reject the null hypothesis is n=100 patients, 50 patients in each treatment arm; alpha-error 0.05; power 0.75.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATG Versus hATG and CsA as First Line Treatment in Pediatric Patients With Severe Acquired Aplastic Anemia|
|Actual Study Start Date :||December 10, 2016|
|Estimated Primary Completion Date :||October 20, 2022|
|Estimated Study Completion Date :||October 20, 2022|
|Experimental: Eltrombopag + IST (ATG + CsA)||
Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
Other Name: Revolade
Drug: IST (ATG + CsA)
Other Name: controle
|Active Comparator: IST (ATG + CsA)||
Drug: IST (ATG + CsA)
Other Name: controle
- ORR (CR + PR) [ Time Frame: 4 months ]The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosupressive treatment hATG and CsA increases the overal (partial + complete) response rate at four months in untreated children with severe aquired aplastic anemia.
- Platelet count [ Time Frame: 4 and 6 months ]
- Hemoglobin [ Time Frame: 4 and 6 months ]
- Neutrophil count [ Time Frame: 4 and 6 months ]
- Cumulative incidence of response [ Time Frame: 4 and 6 months ]
- Duration of hematologic response [ Time Frame: 2 years ]Time from the date of the start of response to the date of relapse defined as again meeting criteria for severe or moderate aplastic anemia
- Overall survival [ Time Frame: 2 years ]
- Event-free survival [ Time Frame: 2 years ]
- Cumulative incidence of relapse [ Time Frame: 2 years ]
- Cumulative incidences of clonal evolution [ Time Frame: 2 years ]
- Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence [ Time Frame: 2 years ]
- Cumulative incidence of adverce effects [ Time Frame: 4 months ]Number of participants with severe adverse events (3-5 stage CTCAE v.4.0) associated with assessment of eltrombopag usage in patients with severe aplastic anemia in 4 months after first day of treatment. Death before evidence of adverce event is competing event.
- Cumulative incidence of adverce effects [ Time Frame: 4 months ]Number of participants with severe adverse events (3-5 stage CTCAE v.4.0) associated with assessment of eltrombopag dose in patients with severe aplastic anemia in 4 months after first day of treatment. Death before evidence of adverce event is competing event.
- Comparison of cumulative incidence of adverce effects in two arms [ Time Frame: 2 years ]comparison between two arms of number of participants with severe adverse events (3-5 stage CTCAE v.4.0) associated with treatment in patients with severe aplastic anemia in 2 years after first day of treatment with death before evidence of adverce event as a competing event.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413306
|Contact: Olga Goronkova, MD||+7-495-287-65-70 ext firstname.lastname@example.org|
|Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology||Recruiting|
|Moscow, Russian Federation, 117198|
|Contact: Zhanna Shekhovtsova 4956647078 email@example.com|
|Contact: Eugene Pashanov, Prof. PhD +79262205578 firstname.lastname@example.org|
|Sub-Investigator: Olga Goronkova|
|Principal Investigator:||Galina Novichkova||Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology|
|Principal Investigator:||Alexei Maschan||Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology|